Abstract
Reference methods were used to determine the potency of LY333328, a semisynthetic glycopeptide derivative with a key N-alkylation substitution, against 833 strains (393 gram-positive strains and representative gram-negative bacilli) with various defined resistance mechanisms. The MICs at which 90% of the isolates are inhibited (MIC90S) (in micrograms per milliliter) of LY333328 and the percentages of strains at < or = 8 micrograms/ml were as follows: for oxacillin-susceptible Staphylococcus aureus, 2 and 100%, and for oxacillin-resistant Staphylococcus aureus, 4 and 100%; for oxacillin-susceptible Staphylococcus epidermis, 4 and 100%, and for oxacillin-resistant Staphylococcus aureus, 8 and 96%; for Streptococcus serogroups A, B, C, and G, 0.25 to 1 and 100%; for Streptococcus pneumoniae < or = 0.015 to 0.06 and 100%; for Enterococcus faecalis, 2 and 100%; and for vancomycin-susceptible Enterococcus faecium, 0.25 and 100%, and for vancomycin-resistant Enterococcus faecium, 4 and 100%. LY333328 was not active (MIC50, > or = 16 micrograms/ml) against more than 400 representative strains of Enterobacteriaceae, pseudomonads, Acinetobacter spp., Stenotrophomonas maltophilia, Haemophilus influenzae, Moraxella catarrhalis, pathogenic Neisseria spp., and anaerobic gram-negative bacilli. Gram-positive anaerobes were LY333328 susceptible (MICs, < or = 2 micrograms/ml). Test methods and conditions may have affected MICs of LY333328, with most (species variation) agar dilution MICs being greater than the broth microdilution MICs.
Full Text
The Full Text of this article is available as a PDF (223.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andrew J. H., Wale M. C., Wale L. J., Greenwood D. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J Antimicrob Chemother. 1987 Aug;20(2):213–221. doi: 10.1093/jac/20.2.213. [DOI] [PubMed] [Google Scholar]
- Cormican M. G., Jones R. N. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Drugs. 1996;51 (Suppl 1):6–12. doi: 10.2165/00003495-199600511-00004. [DOI] [PubMed] [Google Scholar]
- Doern G. V., Brueggemann A., Holley H. P., Jr, Rauch A. M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996 May;40(5):1208–1213. doi: 10.1128/aac.40.5.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N. Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity. Antimicrob Agents Chemother. 1989 Sep;33(9):1652–1653. doi: 10.1128/aac.33.9.1652. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Sader H. S., Erwin M. E., Anderson S. C. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. Diagn Microbiol Infect Dis. 1995 Feb;21(2):85–93. doi: 10.1016/0732-8893(94)00147-o. [DOI] [PubMed] [Google Scholar]
- Perl T. M., Wenzel R. P., Jones R. N. In-vitro activity of LY264826, an investigational glycopeptide antibiotic, against gram-positive bloodstream isolates and selected gram-negative bacilli. J Antimicrob Chemother. 1992 May;29(5):596–598. doi: 10.1093/jac/29.5.596. [DOI] [PubMed] [Google Scholar]
- Schwalbe R. S., Stapleton J. T., Gilligan P. H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987 Apr 9;316(15):927–931. doi: 10.1056/NEJM198704093161507. [DOI] [PubMed] [Google Scholar]